Global Depression Treatment Market Research and Analysis, 2014-2020
Global depression treatment market is facing stiff decline. The market is expected to grow at low CAGR of 1% for the forecasted period of 2015-2020. One of the major factors for such low growth is rapid decline in the revenue of branded drug manufacturers and growing strength of generic drug manufacturers. The patent cliff has caused decline in revenues ranging from few million dollars to billions. The patent expiration and generic drug manufacturers gaining licences to manufacturers has forced many branded drug manufacturers to either stop their R&D or to reduce budgets. There are very limited number of new drugs in the pipeline. Branded drugs sales have declined from $15 billion in 2006 to $9 billion in 2013. Decline in revenues is majorly due to fall in the price of once expensive drugs by over 50-90 percent. Volume shipment are still high and increasing especially in emerging markets.
However, markets for therapies using medical devices such as Vagus nerve stimulation, deep brain stimulation and smart phones is rising. The devices market is expected to grow with a CAGR of 9.2%. Introduction of virtual reality in the treatment of disorders such as post-traumatic stress disorders is also driving the market.
North America and Europe currently are the leading markets. They make up for 70% of the total depression treatment market. The markets are driven by high awareness regarding depression and availability of drugs and therapies. However, the patent cliff has caused decline in the growth rates of the market. Asia Pacific will have the highest growth rate. Recently the discussion over effects of depression on the economies has been going on. Countries such as India, China and Japan are spending on the research of new treatment methods for treating depression. It is expected that new Asian companies could develop new branded drugs in the near future.
However, markets for therapies using medical devices such as Vagus nerve stimulation, deep brain stimulation and smart phones is rising. The devices market is expected to grow with a CAGR of 9.2%. Introduction of virtual reality in the treatment of disorders such as post-traumatic stress disorders is also driving the market.
North America and Europe currently are the leading markets. They make up for 70% of the total depression treatment market. The markets are driven by high awareness regarding depression and availability of drugs and therapies. However, the patent cliff has caused decline in the growth rates of the market. Asia Pacific will have the highest growth rate. Recently the discussion over effects of depression on the economies has been going on. Countries such as India, China and Japan are spending on the research of new treatment methods for treating depression. It is expected that new Asian companies could develop new branded drugs in the near future.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. ANALYST INSIGHT
2.5.1. KEY FINDINGS
2.5.2. RECOMMENDATION
2.5.3. CONCLUSION
2.6. REGULATION
2.6.1. TAX LAWS
2.6.1.1. UNITED STATES
2.6.1.2. EUROPEAN UNION
2.6.1.3. CHINA
2.6.1.4. INDIA
2.6.1.5. REST OF THE WORLD
2.6.2. DRUG AND DEVICES REGULATIONS
2.6.2.1. UNITED STATES
2.6.2.2. EUROPEAN UNION
2.6.2.3. CHINA
2.6.2.4. INDIA
2.6.2.5. REST OF THE WORLD
2.7. TYPE OF DEPRESSION DISORDERS
2.7.1. MAJOR DEPRESSION
2.7.2. BIPOLAR DEPRESSION
2.7.3. SEASONAL AFFECTIVE DISORDER
2.7.4. PSYCHOTIC DEPRESSION
2.7.5. POSTPARTUM DEPRESSION
2.7.6. ATYPICAL DEPRESSION
2.7.7. PERSISTENT DEPRESSIVE DISORDER
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE AND INCIDENCE OF MENTAL HEALTH DISORDERS
3.1.2. INCREASING AWARENESS RELATED TO MENTAL HEALTH DISORDERS
3.1.3. RISING MARKET FOR CHEAPER GENERIC DRUGS
3.2. RESTRAINT
3.2.1. HIGH COST OF THERAPIES
3.2.2. SIDE EFFECTS OF DEPRESSION DRUGS
3.2.3. EXPIRING PATENTS AND DRYING PIPELINES
3.3. OPPORTUNITY
3.3.1. EMERGING MARKETS
3.3.2. NEW THERAPIES SUCH AS VIRTUAL REALITY
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020
5.1.1. GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.4. GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.5. GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.6. GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.7. GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.1. GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.2. GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.3. GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.4. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.1. GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.2. GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.3. GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.4. GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.5. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3. GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.1. GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.2. GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.3. GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.4. GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.5. GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.6. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. PFIZER
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. GLAXOSMITHKLINE
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. FOREST LABS
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. SUN PHARMA
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. ELI LILY AND COMPANY
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. H. LUNDBECK A/S
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. JOHNSON AND JOHNSON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. MERCK AND CO.
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. ASTRAZENECA
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. NOVARTIS
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. SANOFI-AVENTIS
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. TEVA PHARMACEUTICALS
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. OTSUKA PHARMACEUTICALS
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. TAKEDA PHARMACEUTICALS
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. TEVA PHARMACEUTICALS
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. CYBERONICS INC. (LIVANOVA)
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. ALEVI NEUROTHERAPEUTICS
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. BRISTOL MYERS SQUIBB
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. MAYO CLINIC
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. NEUROSTAR
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. ANALYST INSIGHT
2.5.1. KEY FINDINGS
2.5.2. RECOMMENDATION
2.5.3. CONCLUSION
2.6. REGULATION
2.6.1. TAX LAWS
2.6.1.1. UNITED STATES
2.6.1.2. EUROPEAN UNION
2.6.1.3. CHINA
2.6.1.4. INDIA
2.6.1.5. REST OF THE WORLD
2.6.2. DRUG AND DEVICES REGULATIONS
2.6.2.1. UNITED STATES
2.6.2.2. EUROPEAN UNION
2.6.2.3. CHINA
2.6.2.4. INDIA
2.6.2.5. REST OF THE WORLD
2.7. TYPE OF DEPRESSION DISORDERS
2.7.1. MAJOR DEPRESSION
2.7.2. BIPOLAR DEPRESSION
2.7.3. SEASONAL AFFECTIVE DISORDER
2.7.4. PSYCHOTIC DEPRESSION
2.7.5. POSTPARTUM DEPRESSION
2.7.6. ATYPICAL DEPRESSION
2.7.7. PERSISTENT DEPRESSIVE DISORDER
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE AND INCIDENCE OF MENTAL HEALTH DISORDERS
3.1.2. INCREASING AWARENESS RELATED TO MENTAL HEALTH DISORDERS
3.1.3. RISING MARKET FOR CHEAPER GENERIC DRUGS
3.2. RESTRAINT
3.2.1. HIGH COST OF THERAPIES
3.2.2. SIDE EFFECTS OF DEPRESSION DRUGS
3.2.3. EXPIRING PATENTS AND DRYING PIPELINES
3.3. OPPORTUNITY
3.3.1. EMERGING MARKETS
3.3.2. NEW THERAPIES SUCH AS VIRTUAL REALITY
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020
5.1.1. GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.4. GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.5. GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.6. GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.7. GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.1. GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.2. GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.3. GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.4. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.1. GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.2. GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.3. GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.4. GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.5. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3. GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.1. GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.2. GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.3. GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.4. GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.5. GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.3.6. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. PFIZER
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. GLAXOSMITHKLINE
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. FOREST LABS
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. SUN PHARMA
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. ELI LILY AND COMPANY
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. H. LUNDBECK A/S
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. JOHNSON AND JOHNSON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. MERCK AND CO.
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. ASTRAZENECA
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. NOVARTIS
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. SANOFI-AVENTIS
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. TEVA PHARMACEUTICALS
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. OTSUKA PHARMACEUTICALS
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. TAKEDA PHARMACEUTICALS
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. TEVA PHARMACEUTICALS
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. CYBERONICS INC. (LIVANOVA)
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. ALEVI NEUROTHERAPEUTICS
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. BRISTOL MYERS SQUIBB
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. MAYO CLINIC
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. NEUROSTAR
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
LIST OF TABLES
TABLE # 1 GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020
TABLE # 2 GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL UNI-POLAR OR MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL DYSTHYMIA OR DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 7 GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 25 GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 26 GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 27 GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 28 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 1 GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020
TABLE # 2 GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL UNI-POLAR OR MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL DYSTHYMIA OR DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 7 GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 25 GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 26 GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 27 GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 28 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. PFIZER
2. GLAXOSMITHKLINE
3. FOREST LABS
4. SUN PHARMA
5. ELI LILY AND COMPANY
6. H. LUNDBECK A/S
7. JOHNSON AND JOHNSON
8. MERCK AND CO.
9. ASTRAZENECA
10. NOVARTIS
11. SANOFI-AVENTIS
12. TEVA PHARMACEUTICALS
13. OTSUKA PHARMACEUTICALS
14. TAKEDA PHARMACEUTICALS
15. TEVA PHARMACEUTICALS
16. CYBERONICS INC. (LIVANOVA)
17. ALEVI NEUROTHERAPEUTICS
18. BRISTOL MYERS SQUIBB
19. MAYO CLINIC
20. NEUROSTAR
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. PFIZER
2. GLAXOSMITHKLINE
3. FOREST LABS
4. SUN PHARMA
5. ELI LILY AND COMPANY
6. H. LUNDBECK A/S
7. JOHNSON AND JOHNSON
8. MERCK AND CO.
9. ASTRAZENECA
10. NOVARTIS
11. SANOFI-AVENTIS
12. TEVA PHARMACEUTICALS
13. OTSUKA PHARMACEUTICALS
14. TAKEDA PHARMACEUTICALS
15. TEVA PHARMACEUTICALS
16. CYBERONICS INC. (LIVANOVA)
17. ALEVI NEUROTHERAPEUTICS
18. BRISTOL MYERS SQUIBB
19. MAYO CLINIC
20. NEUROSTAR
